Alzheimer’s Research & Therapy is now accepting research submissions for consideration in a special series on peripheral biomarkers, planned for publication in summer 2013.
The publication of these articles will be co-ordinated with a series of commissioned reviews and opinions, edited by Douglas Galasko (UCSD) and written by leaders in the field including Thomas Kodadek (The Scripps Research Institute), Ralph Martins (Edith Cowans University), Sudha Seshadri (Boston) and John Trojanowski (Pennsylvania).
Submit your paper to this series and receive a 50% article processing charge discount – simply quote ‘alzrtPB’ at submission.
A huge research effort has been expended on identifying peripheral biomarkers in plasma, serum or blood cells, in relation to Alzheimer’s disease (AD). Despite progress in recent years, a validated set of biomarkers still has not emerged.
We welcome research manuscripts to accompany a series of reviews addressing the conceptual and methodological issues surrounding the quest to identify blood biomarkers for AD in general, as well as biomarker approaches that have yielded interesting data that may help to advance this field. Our selected examples include plasma A-beta, multiplex plasma biomarkers, biomarkers to evaluate risk of incident AD, and novel approaches to biomarker discovery.
The deadline for submissions is 31st May 2013. Please submit online and indicate in your covering letter that you would like the article to be considered for the peripheral biomarker series.
Benefits of publishing in Alzheimer’s Research & Therapy include:
• International and rapid peer–review (first decision provided within 6 weeks)
• Prestigious Editorial Board
• Receiving first Impact Factor in June 2013
• Immediate publication on acceptance, no color figure charges or space limits and guaranteed unlimited global visibility for your research that open access publishing provides
• Inclusion in PubMed and PubMed Central and indexed in Web of Science database/Science citation index Expanded (SciSearch)
If you would like to enquire about the suitability of a study for consideration, please email email@example.com.